akers of over-the-counter drugs may soon pay for federal review of their products, just like pharmaceutical makers. And they’re fine with the change.

After years of discussion, the Food and Drug Administration appears poised to make that change as part of a sweeping overhaul of its regulations for OTC products. But during a stakeholder meeting on the topic Wednesday afternoon, it was clear that many specifics about the program will be foggy until Congress acts.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.